CO.DON - a ReLive company

Together, stronger. Making lasting differences in patient’s lives globally.

In January 2023, CO.DON GmbH was acquired by ReLive Biotechnologies Ltd., a pioneering global biotech company striving to make a lasting impact in regenerative medicine and cell therapy. The acquisition reinvigorates ReLive's growth and expansion in the global regenerative medicine market by incorporating advanced technology and new R&D pipelines, providing fresh momentum to its ambitions. It also rejuvenates CO.DON, strengthening its presence in Germany and other key markets in the EU, and enhancing its image as a leader in ACI.

About ReLive

Regeneration: Our Mission, Your Freedom

ReLive is a pioneering global biotech company specializing in regenerative medicine. Founded in 2021 by a team of distinguished visionaries and experts in regenerative medicine and cell therapy, ReLive is dedicated to developing and manufacturing innovative regenerative therapies to address the unmet clinical needs in the orthopedic field worldwide.

Global Presence, Global Impact

Headquartered in Boston with an integrated R&D center, ReLive’s global platform includes a key operational and commercial presence in Europe through the acquisition of CO.DON GmbH, as well as market access established in Singapore, with additional approvals underway. Leveraging its footprint across the US, Europe, and Asia, ReLive is strategically positioned to expand its global reach and advance its leadership in regenerative therapies worldwide.

Our Vision: Transforming Lives Through Science

At ReLive, our passion for discovery drives our mission. We’re not just advancing regenerative medicine - we’re committed to making a real, lasting difference in patients’ lives worldwide. Join us on our journey to make a meaningful impact.

To learn more about ReLive visit relivebio.com